| Literature DB >> 15134285 |
Jose R Fernandez1, David B Allison.
Abstract
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003. By September 2002, the compound had entered phase III trials for smoking cessation, and these trials were ongoing in September 2003.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15134285
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472